In particular Mendelian randomization analyses [30–32] and a phenome-wide association study [33] have highlighted a higher risk of developing NOD in carriers of genetic variants at the PCSK9 locus that recapitulate the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and myocardial infarction. The gene discussed is PCSK9; the disease is myocardial infarction.